No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CALC CalciMedica
- 5.740
- -0.260-4.33%
Close May 3 16:00 ET
- 5.760
- +0.020+0.35%
Post 18:29 ET
61.65MMarket Cap-411P/E (TTM)
5.990High5.740Low6.74KVolume5.990Open6.000Pre Close39.52KTurnover0.15%Turnover RatioLossP/E (Static)10.74MShares8.59052wk High5.07P/B26.11MFloat Cap1.75052wk Low--Dividend TTM4.55MShs Float530.319Historical High--Div YieldTTM4.17%Amplitude1.750Historical Low5.859Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Acrivon Therapeutics, Inc. (ACRV) and Viking Therapeutics (VKTX)
CalciMedica Announces Last Patient Enrolled In Phase 2b CARPO Trial Of Auxora In Acute Pancreatitis; Full Target Enrollment Of 216 Patients Achieved
CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that the last patient has been enrolled in its Phase 2b CARPO trial of Auxora in acute pancreatitis (AP).
Express News | CalciMedica Inc: Topline Data From Carpo Expected in 2Q 2024
Express News | CalciMedica Inc: Full Target Enrollment of 216 Patients Achieved
Express News | CalciMedica Announces Last Patient Enrolled in Phase 2B Carpo Trial of Auxora™ in Acute Pancreatitis
CalciMedica And 2 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed lower by around 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders
Comments
ColumnsToday's Morning Movers and Top Ratings: MSFT, ZI, AAL, HSY and More
Morning Movers
Gapping up
$ZoomInfo(ZI.US$ The software stock popped 5.5% after Bank of America analyst Koji Ikeda upgraded it to buy from neutral. “We believe it is a classic self-help story that is set to outperform,” the analyst wrote, underscoring the company’s revenue growth reacceleration and new AI products as potential catalysts.
$Boeing(BA.US$ stock rose 0.9% after Ryanair, Europe's largest airline by passenger number...
Gapping up
$ZoomInfo(ZI.US$ The software stock popped 5.5% after Bank of America analyst Koji Ikeda upgraded it to buy from neutral. “We believe it is a classic self-help story that is set to outperform,” the analyst wrote, underscoring the company’s revenue growth reacceleration and new AI products as potential catalysts.
$Boeing(BA.US$ stock rose 0.9% after Ryanair, Europe's largest airline by passenger number...
20
$CalciMedica(CALC.US$ moving on up
$CalciMedica(CALC.US$ what is happening here?
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg